Azintuxizumab (CAS: 1826819-57-1) is a human IgG4κ monoclonal antibody that targets SLAMF7, a protein found on multiple myeloma cells. It helps create antibody-drug conjugates (ADCs), such as Azintuxizumab vedotin, which deliver cytotoxic agents directly to SLAMF7-expressing tumor cells.
Key Features:
- Target Specificity: Binds to SLAMF7, highly expressed on multiple myeloma cells.
- Mechanism: Used in ADCs to deliver cytotoxic drugs directly to tumor cells.
- Therapeutic Potential: Investigated for treating multiple myeloma.
Applications:
- Cancer Research: Helps develop ADCs that target SLAMF7-expressing tumors, enhancing treatment precision and reducing toxicity.
- ADC Development: Can be used to synthesize Azintuxizumab vedotin for targeted cancer therapy.
Handling and Storage:
- Storage: Store at -20°C, protected from light.
- Precautions: Use personal protective equipment and ensure proper ventilation.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
